Log in
NASDAQ:VRNA

VERONA PHARMA P/S Stock Forecast, Price & News

$6.43
+0.21 (+3.38 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$6.23
Now: $6.43
$6.60
50-Day Range
$6.22
MA: $7.27
$8.50
52-Week Range
$2.01
Now: $6.43
$15.71
Volume39,827 shs
Average Volume662,207 shs
Market Capitalization$84.66 million
P/E RatioN/A
Dividend YieldN/A
Beta0.35
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Read More
VERONA PHARMA P/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRNA
CUSIPN/A
Phone44-20-3283-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.28 per share

Profitability

Net Income$-40,780,000.00

Miscellaneous

Employees22
Market Cap$84.66 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$6.43
+0.21 (+3.38 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions

How has VERONA PHARMA P/S's stock price been impacted by COVID-19 (Coronavirus)?

VERONA PHARMA P/S's stock was trading at $4.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VRNA shares have increased by 32.9% and is now trading at $6.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of VERONA PHARMA P/S?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for VERONA PHARMA P/S
.

When is VERONA PHARMA P/S's next earnings date?

VERONA PHARMA P/S is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for VERONA PHARMA P/S
.

How were VERONA PHARMA P/S's earnings last quarter?

VERONA PHARMA P/S (NASDAQ:VRNA) issued its quarterly earnings data on Friday, August, 14th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.28.
View VERONA PHARMA P/S's earnings history
.

What price target have analysts set for VRNA?

4 brokers have issued 1 year price targets for VERONA PHARMA P/S's shares. Their forecasts range from $17.00 to $34.00. On average, they anticipate VERONA PHARMA P/S's stock price to reach $22.75 in the next year. This suggests a possible upside of 253.8% from the stock's current price.
View analysts' price targets for VERONA PHARMA P/S
.

Are investors shorting VERONA PHARMA P/S?

VERONA PHARMA P/S saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 88,000 shares, an increase of 1,213.4% from the August 31st total of 6,700 shares. Based on an average trading volume of 1,690,000 shares, the short-interest ratio is presently 0.1 days.
View VERONA PHARMA P/S's Short Interest
.

Who are some of VERONA PHARMA P/S's key competitors?

What other stocks do shareholders of VERONA PHARMA P/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VERONA PHARMA P/S investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Novavax (NVAX), SCYNEXIS (SCYX), Vaxart (VXRT), Abbott Laboratories (ABT), Citius Pharmaceuticals (CTXR) and electroCore (ECOR).

Who are VERONA PHARMA P/S's key executives?

VERONA PHARMA P/S's management team includes the following people:
  • Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)
  • Mr. Piers John Morgan, Chief Financial Officer (Age 53)
  • Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)
  • Ms. Victoria Stewart, Director of Communications
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57)

When did VERONA PHARMA P/S IPO?

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is VERONA PHARMA P/S's stock symbol?

VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."

Who are VERONA PHARMA P/S's major shareholders?

VERONA PHARMA P/S's stock is owned by many different retail and institutional investors. Top institutional investors include D.A. Davidson & CO. (0.89%) and Wedbush Securities Inc. (0.83%).

Which institutional investors are buying VERONA PHARMA P/S stock?

VRNA stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., and D.A. Davidson & CO..

How do I buy shares of VERONA PHARMA P/S?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VERONA PHARMA P/S's stock price today?

One share of VRNA stock can currently be purchased for approximately $6.43.

How big of a company is VERONA PHARMA P/S?

VERONA PHARMA P/S has a market capitalization of $84.66 million. The company earns $-40,780,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis. VERONA PHARMA P/S employs 22 workers across the globe.

What is VERONA PHARMA P/S's official website?

The official website for VERONA PHARMA P/S is www.veronapharma.com.

How can I contact VERONA PHARMA P/S?

VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.